News

Article

Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer

Fact checked by:

Key Takeaways

  • Certepetide addition showed potential benefits in overall survival and objective response rates despite no PFS improvement in metastatic PDAC.
  • Safety profiles were similar between investigational and control arms, with comparable grade 3 or greater adverse effects.
SHOW MORE

Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.

Pancreatic Cancer | Image Credit: © Crystal light - stock.adobe.com

Pancreatic Cancer | Image Credit: ©
Crystal light - stock.adobe.com

The addition of the novel cyclic peptide certepetide to gemcitabine and nab-paclitaxel (Abraxane) demonstrated signs of efficacy despite failing to improve progression-free survival (PFS) vs chemotherapy alone in patients with untreated metastatic pancreatic ductal adenocarcinoma (PDAC), according to data from the phase 2 ASCEND trial (NCT05042128) that were presented at the 2025 Gastrointestinal Cancers Symposium.

Results revealed that the 6-month PFS rate was 49.0% (95% CI, 36.4%-60.5%) in the investigational arm vs 40.8% (95% CI, 22.6%-58.3%) in the control arm, with a median PFS of 5.5 months in both arms (HR, 0.96; 95% CI, 0.60-1.53; log-rank P = .85). The median overall survival (OS) was 12.42 months in the investigational arm vs 9.72 months in the control arm (HR, 0.95; 95% CI, 0.56-1.60; log-rank P = .82). The objective tumor response rates (OTRRs) were 38.3% and 26.9% for the investigational and control arms, respectively.

“The addition of certepetide is safe and despite showing no improvement in 6-month PFS, a possible signal of benefit in OS and ORR (including 4 complete responses) was observed, warranting further investigation,” lead study author Andrew Dean, MBChB, MRCP (UK), FRACP, head of the Department of Medical Oncology at St John of God Subiaco Hospital, and a consultant at GenesisCare at Shenton House in Perth, Australia, and coauthors, wrote in the poster. “A further cohort (cohort B) of the ASCEND study evaluating the addition of a second dose of certepetide is ongoing.”

Gemcitabine plus nab-paclitaxel is a standard frontline therapy for patients with advanced and metastatic PDAC. Certepetide is a novel cyclic peptide that enhances the penetration of concurrently administered drugs into the tumor and stroma, resulting in potentially increased antineoplastic activity.

The randomized, double-blind, multicenter ASCEND was designed to evaluate the impact of adding certepetide to this chemotherapy backbone in this population.

Eligible patients had histologically confirmed advanced PDAC suitable for therapy with gemcitabine and nab-paclitaxel. Patients were also required to have measurable disease per RECIST 1.1 and an ECOG performance status of 0 or 1. Patients were randomly assigned 1:1 to 3.2 mg/kg of certepetide (n = 65) or placebo (n = 30) on days 1, 8, and 15 of a 28-day cycle, both in combination with 1,000 mg/m2 of intravenous (IV) gemcitabine and 125 mg/m2 of IV nab-paclitaxel.

Patients underwent a minimum 18-month follow-up period, during which data were evaluated for PFS, OTRR, OS, safety, patient-reported outcomes (PROs), exploratory research biomarkers, and E-PRO feasibility.

A total of 198 patients were screened; 66 patients were allocated to the investigational arm and 29 were allocated to the placebo arm between May 2022 and December 2023. One patient from each arm did not receive the allocated intervention and were omitted from the full analysis set.

The primary analysis was conducted with 70 total deaths.

Baseline characteristics in the overall population (n = 95) indicated that the mean age was 65 years (range, 37-86) and most patients were male (60%) and had an ECOG performance status of 1 (54%). The pancreatic tumor location was found in the body (19%), head (44%), and tail (31%), and was unknown in 6.3% of cases. Adenocarcinoma represented the most common histologic subtype (89%) followed by poorly differentiated carcinoma (11%). Most patients had stage IV disease (96%) as opposed to stage III disease (4%) according to the 8th edition of the AJCC. Sites of metastatic disease included the liver (73%), pulmonary tract (28%), peritoneum (21%), and other (28%). Prior treatment included systemic therapy (15%) and surgery (19%).

Additional findings indicated that among patients with an ECOG performance status of 0, the 6-month PFS rate was 68.1% (95% CI, 48.7%-81.4%) in the investigational arm vs 36.4% (95% CI, 11.2%-62.7%) in the control arm.

In terms of safety, grade 3/4 adverse effects (AEs) that occurred in at least 10% of patients included decreased neutrophil count (investigational: 18% vs control: 8%), anemia (14%; 4%), decreased platelet count (12%; 4%), peripheral sensory neuropathy (9%; 4%), febrile neutropenia (8%; 3%), lung infection (8%; 3%), fatigue (6%; 3%), sepsis (6%; 3%), thromboembolic event (6%; 2%), and increased alanine aminotransferase levels (5%; 2%).

Reference

Dean A, Sjoquist K, Gebski V, et al. AGITG ASCEND: randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: initial results. J Clin Oncol. 2024;43(suppl 4):728. doi:10.1200/JCO.2025.43.4_suppl.728

Related Videos
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health
Kanwal PS Raghav, MBBS, MD